MEDIAN TECHNOLOGIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3 EUR | -9.09% |
|
-12.92% | -36.84% |
| 2023 | European Investment Bank OKs Median Technologies' Draw Down of Final EUR8.5 Million Loan Tranche | MT |
| 2023 | Median: final tranche of EIB loan approved | CF |
| Sales 2023 * | 23.9M 25.55M | Sales 2024 * | 29.6M 31.65M | Capitalization | 55.13M 58.94M |
|---|---|---|---|---|---|
| Net income 2023 * | -23M -24.59M | Net income 2024 * | -26M -27.8M | EV / Sales 2023 * | 2.71 x |
| Net Debt 2023 * | 9.73M 10.41M | Net Debt 2024 * | 34.25M 36.62M | EV / Sales 2024 * | 3.02 x |
| P/E ratio 2023 * |
-2.26
x | P/E ratio 2024 * |
-2.33
x | Employees | 233 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 85.99% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -9.09% | ||
| 1 week | -12.92% | ||
| Current month | +20.97% | ||
| 1 month | +14.94% | ||
| 3 months | -25.56% | ||
| 6 months | -35.06% | ||
| Current year | -36.84% |
1 week
2.58
3.52
1 month
2.334.08
Current year
2.335.06
1 year
2.336.77
3 years
2.3318.32
5 years
0.9318.32
10 years
0.9018.32
| Managers | Title | Age | Since |
|---|---|---|---|
Fredrik Brag
FOU | Founder | 62 | 01-12-31 |
| Director of Finance/CFO | - | 21-07-11 | |
Yan Liu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Oern Stuge
BRD | Director/Board Member | 70 | 20-06-24 |
Oran Muduroglu
CHM | Chairman | 62 | 08-03-25 |
Timothy Haines
BRD | Director/Board Member | 67 | 15-11-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3 | -9.09% | 211,693 |
| 24-04-25 | 3.3 | 0.00% | 7,219 |
| 24-04-24 | 3.3 | -1.20% | 16,286 |
| 24-04-23 | 3.34 | -3.61% | 25,225 |
| 24-04-22 | 3.465 | +0.58% | 44,730 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am EDT
More quotes
Median Technologies offers innovative imaging solutions and services to improve healthcare for all. The group uses the power of phenomic imaging to contribute to the emergence of new therapies and treatment strategies for patients. Its solutions, «iSee» for the image management in oncology trials and «iBiopsy», its phenomic imaging platform, combined with the expertise of its teams are an essential part to the discovery of new drugs and diagnostic tools to monitor diseases and evaluate the response of patients to their therapy. Median Technologies is helping biopharmaceutical companies and healthcare professionals quickly and accurately introduce new treatments to patients who need them, with a view to reducing overall costs of care.
Provision of services accounts for all net sales.
Net sales are distributed geographically as follows: France (4%), the United States and Canada (37%), China (19.2%), the United Kingdom (18.9%) and other (20.9%).
Calendar
2024-10-16
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3
EUR
Average target price
24.18
EUR
Spread / Average Target
+705.83%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.84% | 58.85M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- ALMDT Stock
